4D Molecular Therapeutics, Inc. (FDMT) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $13.26: Quality below floor (2.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 5.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 29%; Below-average business quality.
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead... Read more
Sell if holding. Engine safety override at $13.26: Quality below floor (2.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 5.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 29%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.1/10, moderate confidence.
Passes 6/7 gates (positive momentum, favorable risk/reward ratio, no SEC red flags, earnings proximity 37d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
Recent developments
updated 2026-07-05Recent Developments — 4D Molecular Therapeutics, Inc.
Latest news
- NEWS 4D Molecular Therapeutics Completes Enrollment For Its 4FRONT-2 Second Phase 3 Clinical Trial Evaluating 4D-150 In Patie — benzinga Jun 29, 2026 positive
Generated 2026-07-05T09:50:25Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Volatile — 7.9% daily ATR makes tight stops impractical. Position-size conservatively.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $13.26: Quality below floor (2.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 5.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 29%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $12.09. Score 5.1/10, moderate confidence.
Take-profit target: $24.55 (+88.8% upside). Prior stop was $12.09. Stop-loss: $12.09.
Quality below floor (2.1 < 4.0).
4D Molecular Therapeutics, Inc. trades at a P/E of N/A (forward -3.5). TrendMatrix value score: 7.4/10. Verdict: Sell.
17 analysts cover FDMT with a consensus score of 4.1/5. Average price target: $28.
What does 4D Molecular Therapeutics, Inc. do?4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated...
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.